EBMT 2022 | Highlights from EBMT 2022
Markéta Marková, MD, PhD, Institute of Haematology and Blood Transfusion, Prague, Czech Republic, shares her highlights from the EBMT meeting. Dr Marková talks on a study comparing autologous hematopoietic stem cell transplantation (autoHSCT) with chimeric antigen receptor T-cell (CAR-T) therapy in second-line in lymphoma, as well as a lecture about VEXAS syndrome. Dr Marková also mentions a session on transplant decisions and novel drugs in myeloproliferative neoplasms (MPNs). Finally, Dr Marková mentions a study evaluating lenalidomide and azacitidine in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as a presentation on engineered T-cells for graft-versus-host disease (GvHD). This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
